News 1297 views

Belgian VMD acquires Laboratoires Biové

Veterinary medicine manufacturer VMD, based in Arendonk, Belgium, has announced that it has acquired the private French pharmaceutical laboratory Laboratoires Biové.

Biové's offices are located in Arques, the North of France with a strong market presence in other areas of the world including Magreb, the Middle East and South East Asia.

Majority shareholder
Jan Moons (managing director and CEO of VMD) will be the majority shareholder of the new entity with Pierre Stoven (managing director of Biové) retaining a minority stake in the new structure. The board of directors of both companies will be actively involved in the overall management process.

"Both companies will expand independently on a national basis whilst competently continuing to serve all major and existing partnerships," explained Moons.

"The company structures will remain unchanged: internationally, VMD will focus more on enhancing sales & marketing as well as research and development whereas Biové will focus on the production process. Biové will also coordinate all toll manufacturing opportunities directly with their existing network."

Wide range
The company provides a wide range of registered antibiotics, vitamins and chemotherapeutics in the form of injectable preparations, water soluble powders and premixes relating to the treatment of animal diseases that mainly affect large animals.

VMD, privately owned, is market leader in its field in Belgium. Its veterinary medicines are currently marketed in more than 70 other countries worldwide through a network of distributors and VMD subsidiaries in Hungary, Turkey and Nigeria.

Laboratoires Biové
The pharmaceutical laboratory Laboratoires Biové produces its own product range in France, mainly for productive livestock, i.e. livestock intended for human consumption (for example, bovines, poultry, fish and bees) as well as dedicated formulations for pets.

Related website:

For the latest pig news, subscribe here

Editor PigProgress

Or register to be able to comment.